Normal Death: A Comprehensive Multidisciplinary Review of the Physiological Mechanisms, Molecular Pathways, Clinical Course, Geriatric Considerations, and Ethical Frameworks of the Natural Dying Process

Abstract

Death is an inevitable biological event, yet modern healthcare often struggles to acknowledge normal dying as a natural culmination of life. Misunderstandings about the physiological and molecular pathways involved can lead to unnecessary interventions, patient distress, and family confusion. This review aims to synthesize current evidence on the physiological mechanisms, molecular pathways, clinical course, geriatric factors, psychosocial aspects, and ethical frameworks that define normal dying. It highlights how this knowledge can guide compassionate, evidence-based palliative care and shape healthcare policy. A multidisciplinary narrative review was conducted, social sciences. Key sources include primary research articles, clinical guidelines, and landmark conceptual works relevant to end-of-life care. The review identifies terminal physiological decline as an orchestrated process involving homeostatic failure, multi-organ shutdown, and regulated cellular pathways such as senescence and apoptosis. Molecular contributors include telomere shortening, mitochondrial dysfunction, oxidative stress, and chronic inflammation. Clinically, signs of the active dying phase, appropriate symptom management, and sensitive communication with families are critical. Geriatric considerations reveal how frailty, comorbidities, and cultural factors uniquely shape dying in older adults. Gaps in prognostication tools, molecular biomarkers, and cross-cultural research remain. Normalizing the concept of natural dying can reduce medicalization, improve quality of life at the end stage, and empower families and healthcare teams to honor patient preferences. Ongoing education, policy support, and research into molecular and cultural dimensions are essential for dignified, person-centered end-of-life care.

Keywords

Introduction

1.1. Definition of “Normal” or “Natural” Death

Normal or natural death is broadly defined as the physiological cessation of life due to intrinsic biological aging processes, occurring without the direct influence of external traumatic factors or medical interventions intended to prolong life (Pereira et al., 2020). Unlike sudden or accidental death, normal death typically results from the gradual decline of multiple organ systems and the eventual failure of vital physiological functions. The World Health Organization (WHO) acknowledges natural death as a part of the normal human life course, emphasizing its distinction from preventable or premature mortality (World Health Organization, 2019).

1.2. Historical Perspectives on Dying and Death

Cultural and philosophical interpretations of death have evolved significantly over time. In ancient societies, death was often ritualized and integrated into communal life, with traditions varying widely across civilizations (Ariès, 1981). Philippe Ariès, in his seminal work The Hour of Our Death, describes how pre-modern communities accepted death as a familiar and communal event, whereas in modern industrialized societies, death has become increasingly medicalized and institutionalized (Ariès, 1981; Kellehear, 2007). The 20th century saw a significant shift from home-based dying to hospital-based dying, creating new ethical, clinical, and social challenges around the management of end-of-life care (Kellehear, 2007).

1.3. Rationale for a Multidisciplinary Review

Understanding normal death requires perspectives that go beyond purely medical explanations. It is inherently a multidisciplinary phenomenon, encompassing physiology, molecular biology, geriatrics, ethics, sociology, and palliative care (Gawande, 2014). As societies age and life expectancy increases, there is a growing need for integrative knowledge that clarifies the biological mechanisms of the dying process while addressing the psychosocial and ethical dimensions of end-of-life care (Reynolds & Botha, 2022). A comprehensive synthesis can help bridge gaps between biomedical science and humane care, informing healthcare professionals, policymakers, patients, and families alike.

1.4. Objectives and Significance of the Paper

This review paper aims to:

• Elucidate the physiological and molecular pathways that characterize the natural dying process.
• Examine the clinical signs and trajectories commonly observed during normal death, especially in geriatric populations.
• Highlight the ethical, cultural, and legal frameworks that influence end-of-life decisions and care practices.
• Promote an integrated understanding that supports dignified, compassionate, and evidence-based end-of-life care.

By consolidating diverse strands of knowledge, this paper seeks to normalize discourse around death, reduce unnecessary medical interventions, and strengthen palliative care approaches that honor the natural culmination of the human lifespan (Gawande, 2014; Reynolds & Botha, 2022).

2. Physiological Mechanisms of the Natural Dying Process

2.1. Terminal Decline: Overview

2.1.1. Concept of Homeostatic Failure

Normal dying is fundamentally a result of progressive homeostatic failure — the gradual collapse of the body’s ability to maintain internal equilibrium (Lynn & Adamson, 2003). Over time, critical physiological systems, such as cardiovascular, respiratory, renal, and neurological networks, lose functional reserve due to accumulated cellular damage and reduced regenerative capacity (Mitchell et al., 2017). This decline often manifests as frailty, reduced mobility, weight loss, and increased vulnerability to minor stressors that would otherwise be survivable.

2.1.2. Common Pathways Across Organ Systems

Although the primary cause of death may vary — cancer, organ failure, or advanced age — the final pathways often converge toward multi-organ dysfunction, energy depletion, and the body’s inability to sustain vital functions (Murtagh et al., 2011). This integrated failure underlies what is commonly referred to as “the terminal phase.”

2.2. Cardiovascular Shutdown

2.2.1. Decline in Cardiac Output

One of the hallmarks of dying is a progressive reduction in cardiac output, driven by weakened myocardial contractility, arrhythmias, and vascular resistance changes (Briggs et al., 2018). As cardiac function declines, perfusion to vital organs diminishes, leading to tissue hypoxia and metabolic acidosis.

2.2.2. Hypotension and Hypoperfusion

Terminal hypotension is a frequent sign, often accompanied by cool extremities, mottling of the skin, and weak peripheral pulses (Bennett et al., 2009). The loss of vascular tone and failing cardiac output synergistically reduce blood flow, accelerating organ system shutdown.

2.3. Respiratory Changes

2.3.1. Cheyne–Stokes Respiration

In the final days or hours of life, many patients develop Cheyne–Stokes respiration — a cyclic breathing pattern characterized by periods of deep, rapid breathing alternating with apnea (Morita et al., 2003). This pattern reflects impaired brainstem control due to hypoxia and hypercapnia.

2.3.2. Terminal Apnea

Eventually, the respiratory drive fails entirely. Terminal apnea — the complete cessation of breathing — is the ultimate sign of life’s end and occurs once the brainstem centers that regulate ventilation shut down (Weissman & Meier, 2011).

2.4. Neurological Changes

2.4.1. Progressive Loss of Consciousness

Cerebral perfusion decreases as systemic circulation deteriorates, resulting in reduced cortical activity and progressive unconsciousness (Twaddle et al., 2002). Patients may drift into deep somnolence before becoming unresponsive.

2.4.2. Neurochemical Changes in the Brain

Near death, the brain’s neurochemical environment shifts dramatically. Endogenous opioids and neurotransmitters such as serotonin and dopamine may modulate awareness and pain perception (Donovan et al., 2019). This neurochemical adaptation can naturally blunt suffering.

2.4.3. Pain Perception Near Death

While pain is a common concern, evidence suggests that many dying patients experience reduced sensory awareness due to hypoxia and cerebral dysfunction (Twaddle et al., 2002). Nonetheless, appropriate palliative analgesia remains critical to manage distress.

2.5. Renal and Metabolic Changes

2.5.1. Dehydration and Decreased Intake

As death nears, appetite and thirst wane. Voluntary fluid and food intake decline significantly, leading to dehydration, hemoconcentration, and reduced renal perfusion (Stephens et al., 2020).

2.5.2. Electrolyte Imbalances

Renal failure and dehydration cause profound electrolyte derangements — hyperkalemia, acidosis, and uremia — which contribute to cardiac arrhythmias and CNS depression (Stephens et al., 2020).

2.5.3. Multi-Organ System Failure

These metabolic imbalances accelerate the systemic cascade of multi-organ failure, which is the immediate physiological cause of natural death (Mitchell et al., 2017).

2.6. Endocrine and Immune Factors

2.6.1. Hormonal Dysregulation

Endocrine pathways, including cortisol and catecholamine production, become dysregulated. Adrenal insufficiency may occur, further lowering blood pressure and metabolic stability (Bruera & Hui, 2018).

2.6.2. Immune System Exhaustion

Finally, the immune system becomes profoundly weakened. Chronic low-grade inflammation (inflammaging) and reduced cellular immunity increase susceptibility to infections, which often contribute to the final terminal events (Fulop et al., 2018).

3. Molecular Pathways Involved in Normal Death

3.1. Cellular Senescence and Apoptosis

3.1.1. Telomere Shortening

One of the hallmarks of normal aging and natural death is progressive telomere attrition. Telomeres are protective caps at the ends of chromosomes that shorten with each cell division due to the end-replication problem (Blackburn et al., 2015). Critically short telomeres trigger a DNA damage response that halts further cell proliferation, leading to replicative senescence — a state of permanent cell cycle arrest (López-Otín et al., 2013). This senescence limits tissue regeneration and promotes functional decline in organs.

3.1.2. Programmed Cell Death Pathways

Alongside senescence, apoptosis (programmed cell death) is a tightly regulated process that eliminates damaged or dysfunctional cells. In later life, increased DNA damage, oxidative stress, and mitochondrial dysfunction activate intrinsic apoptotic pathways mediated by p53, BAX, and caspase cascades (Elmore, 2007). While apoptosis is protective early in life, its dysregulation contributes to tissue atrophy and organ failure in old age (Childs et al., 2015).

3.2. Oxidative Stress and Mitochondrial Dysfunction

3.2.1. Role of ROS Accumulation

Reactive oxygen species (ROS) are natural by-products of cellular metabolism. With aging, antioxidant defenses decline while ROS production increases, leading to cumulative oxidative damage to DNA, proteins, and lipids (Harman, 2009). This damage accelerates cellular senescence, apoptosis, and inflammation — all key contributors to the dying process (López-Otín et al., 2013).

3.2.2. Mitochondrial Decline

Mitochondria are central to bioenergetics and apoptosis. Age-related mitochondrial dysfunction impairs ATP production, increases ROS generation, and promotes the release of pro-apoptotic factors such as cytochrome c (Bratic & Larsson, 2013). This cascade undermines cellular energy balance and contributes directly to multi-organ failure seen in normal dying.

3.3. Inflammatory Pathways

3.3.1. Chronic Low-Grade Inflammation (Inflammaging)

Normal aging is associated with a persistent, low-grade, systemic inflammatory state known as “inflammaging” (Franceschi et al., 2000). This state is characterized by elevated levels of pro-inflammatory cytokines such as IL-6, TNF-α, and CRP. Inflammaging promotes cellular damage, immune system exhaustion, and progression toward frailty and death (Ferrucci & Fabbri, 2018).

3.3.2. Cytokine Profiles at End of Life

In the final stages of life, dysregulated cytokine expression exacerbates catabolic processes and tissue wasting (Bruunsgaard & Pedersen, 2003). Increased IL-1β and TNF-α contribute to cachexia, anorexia, and the systemic decline that typifies the terminal phase.

Table 1. Key Inflammatory Markers Associated with Aging and Natural Death

( Ferrucci & Fabbri, 2018; Bruunsgaard & Pedersen, 2003)

3.4. Genetic and Epigenetic Factors

3.4.1. Genes Implicated in Longevity and Death

Genetic factors play a significant role in lifespan and the mechanisms of normal death. Variants in genes regulating DNA repair (e.g., WRN, p53), insulin/IGF-1 signaling (e.g., FOXO3A), and antioxidant pathways (e.g., SOD2) have been linked to longevity and age-related decline (Kenyon, 2010). Mutations or reduced function in these genes accelerate senescence and organ failure.

3.4.2. Epigenetic Drift with Aging

Epigenetic modifications — DNA methylation, histone changes, and non-coding RNAs — shift progressively with age, a phenomenon termed “epigenetic drift” (Horvath & Raj, 2018). These alterations dysregulate gene expression, promote genomic instability, and contribute to the loss of cellular function. Recent studies suggest that age-related changes in DNA methylation can even serve as a “biological clock” predicting mortality risk (Horvath & Raj, 2018).

4. Clinical Course of Normal Dying

4.1. Recognizing the Active Dying Phase

4.1.1. Signs and Symptoms

The active dying phase typically occurs during the last hours to days of life and is characterized by predictable physiological changes that indicate the body is shutting down irreversibly (Weissman & Meier, 2011). Common signs include profound weakness, bedbound status, decreased oral intake, loss of swallowing reflex, cool extremities, mottled skin, altered respiratory patterns (such as Cheyne–Stokes breathing or agonal respirations), and fluctuating or decreased consciousness (Dhillon et al., 2020).

Families and caregivers often observe terminal secretions (“death rattle”), irregular pulse, and prolonged pauses in breathing, which can be distressing if not anticipated and explained (Hui et al., 2014).

Table 2. Typical Clinical Signs of the Active Dying Phase

(Weissman & Meier, 2011; Hui et al., 2014)

4.1.2. Prognostication Tools

Accurate recognition of when a patient has entered the active dying phase is essential for guiding care. Prognostication tools, such as the Palliative Performance Scale (PPS) and the Karnofsky Performance Status, help clinicians assess functional decline and survival estimates (Anderson et al., 1996). Clinical judgment is also informed by signs like persistent decreased consciousness, urine output less than 200 mL/day, and the presence of apnea (Hui et al., 2014).

4.2. Palliative Symptom Management

4.2.1. Pain and Dyspnea Relief

Effective symptom management is critical to a comfortable death. Pain is common near the end of life, and opioid analgesics (e.g., morphine) are the mainstay for managing moderate to severe pain (Cherny & Radbruch, 2015).

Dyspnea, or the sensation of breathlessness, is highly prevalent and distressing. Opioids, low-dose benzodiazepines for anxiety, and non-pharmacological measures such as positioning and airflow from a fan can help relieve dyspnea (Bausewein et al., 2008).

4.2.2. Managing Delirium and Agitation

Terminal delirium — characterized by restlessness, agitation, or hallucinations — occurs in up to 85% of dying patients (Lawlor et al., 2000). Antipsychotics like haloperidol are commonly used for symptom control, alongside environmental measures such as family presence, calm surroundings, and reassurance (Lawlor et al., 2000; Hui et al., 2014).

4.3. Communication and Family Involvement

4.3.1. Signs Families Should Understand

Families often fear the visible changes that accompany dying. Honest, compassionate communication about what to expect helps families prepare emotionally and reduces unnecessary medical interventions (Back et al., 2009). It is vital to explain signs like breathing pattern changes, unresponsiveness, and terminal secretions, emphasizing that these are normal and do not indicate suffering if comfort measures are provided.

4.3.2. Advance Care Planning

Advance care planning (ACP) encourages early discussions about patients’ wishes for life-sustaining treatments, preferred place of death, and surrogate decision-makers (Sudore et al., 2017). Clear ACP helps align care with the patient’s goals, reduce unwanted interventions, and support the family’s sense of preparedness and peace.

5. Geriatric Considerations

5.1. Normal Death in the Elderly: Distinct Features

5.1.1. Frailty vs. Disease-Specific Death

Normal dying in older adults often follows a trajectory shaped by frailty rather than a single dominant disease (Clegg et al., 2013). Frailty is characterized by decreased physiological reserve and resistance to stressors, resulting in increased vulnerability to minor illnesses or injuries that can tip the balance toward multi-organ failure (Rockwood et al., 2005). Unlike deaths caused by conditions like advanced cancer or acute stroke, frailty-related dying is gradual and marked by progressive weight loss, weakness, exhaustion, and declining mobility (Fried et al., 2001).

5.1.2. Comorbidities Masking the Dying Process

Multiple chronic conditions — such as dementia, heart failure, diabetes, or COPD — often coexist in older adults and can obscure recognition of the terminal phase (Covinsky et al., 2015). This complexity may delay appropriate palliative interventions, as the dying trajectory may be mistaken for treatable disease exacerbations (Mitchell et al., 2009). Timely identification of irreversible decline remains a key challenge in geriatric palliative care.

5.2. Psychosocial Dimensions in Older Adults

5.2.1. Grief, Loneliness, and Existential Distress

Older adults may experience profound existential and psychosocial challenges as they approach death. Grief for lost relationships, functional independence, and life roles can manifest as loneliness, sadness, or even demoralization (Reynolds & Botha, 2022). Studies show that loneliness is a strong predictor of increased symptom burden, depression, and poorer quality of dying in elderly populations (Victor & Bowling, 2012).

5.2.2. Family Dynamics and Caregiver Burden

Family caregivers play a pivotal role in caring for dying elders, often providing extensive emotional and physical support (Given et al., 2004). However, caregiver burden is substantial — encompassing physical strain, financial stress, and anticipatory grief (Reinhard et al., 2019). Effective family-centered communication, respite resources, and psychosocial support are essential to alleviate caregiver distress and promote a dignified dying process for the elderly.

Table 3. Common Psychosocial Concerns at End-of-Life in Older Adults

(Victor & Bowling, 2012; Reinhard et al., 2019)

5.3. Cultural Attitudes Toward Dying in Old Age

Cultural values and beliefs profoundly shape attitudes toward death in later life. In many cultures, dying in old age is regarded as a natural culmination of the life cycle and may be accompanied by rituals or family caregiving traditions that support the dying person (Kellehear, 2007). In contrast, modern Western societies often medicalize dying, leading to extended hospital stays and invasive treatments even at the end of life (Gawande, 2014).

Respecting cultural preferences is vital in geriatric palliative care. This includes acknowledging diverse views on disclosure of prognosis, truth-telling, use of life-sustaining treatments, and rituals at death (Koenig & Gates-Williams, 1995). Cultural competence helps ensure that end-of-life care is not only clinically appropriate but also aligned with the elder’s and family’s values and beliefs.

6. Implications for Palliative Care and Healthcare Policy

6.1. Integrating Knowledge of Normal Dying in Hospice Care

A clear understanding of the natural dying process is fundamental to the philosophy of hospice and palliative care. By recognizing that death can be a normal biological event rather than a medical failure, care teams can avoid burdensome interventions that offer little benefit near life’s end (Gawande, 2014). Hospice programs emphasize symptom control, psychosocial support, and spiritual care, focusing on comfort rather than cure (Connor, 2018). Integrating current insights into the physiological and molecular pathways of normal dying can further refine individualized care plans, helping clinicians anticipate complications, communicate realistically with families, and minimize unnecessary hospitalizations (Morrison & Meier, 2004).

6.2. Training Healthcare Professionals to Recognize and Support Normal Death

Many physicians and nurses report limited formal training in how to identify and manage the final stages of dying, particularly the subtle signs of terminal decline in frail elderly patients (Billings & Block, 1997). Improved training on prognostication, communication skills, cultural sensitivity, and symptom management empowers healthcare providers to offer compassionate, appropriate end-of-life care (Quill & Abernethy, 2013). Interdisciplinary education — involving doctors, nurses, social workers, and chaplains — promotes a shared understanding of when life-prolonging treatments may no longer align with the patient’s goals, thus encouraging shared decision-making and timely hospice referrals (Quill & Abernethy, 2013; Steinhauser et al., 2000).

6.3. Policies to Support Patient Dignity and Family-Centered Care

Healthcare systems and policymakers play a vital role in promoting death with dignity. Advance care planning, clear documentation of goals of care, and legal frameworks for patient autonomy — such as advance directives and do-not-resuscitate (DNR) orders — protect patients from unwanted aggressive treatments (Sudore et al., 2017). Policies that expand access to home-based hospice, community palliative care teams, and caregiver support services help families provide care aligned with the patient’s values and reduce the risk of medicalization of dying (Connor, 2018).

Furthermore, reimbursement structures that incentivize high-value, patient-centered palliative services over aggressive, low-benefit interventions are critical to shifting practice toward dignified, evidence-based end-of-life care (Morrison & Meier, 2004).

7. Future Directions and Research Gaps

7.1. Emerging Molecular Insights

Understanding the molecular basis of normal dying remains an evolving frontier. While considerable progress has been made in mapping cellular senescence, apoptosis, oxidative stress, and inflammaging (López-Otín et al., 2013), significant questions persist about how these mechanisms integrate to shape individual dying trajectories. Advanced ‘omics’ approaches — genomics, epigenomics, proteomics, and metabolomics — offer new opportunities to map biological pathways that govern the terminal decline (Kennedy et al., 2014). Future research should focus on large-scale longitudinal studies that correlate molecular changes with clinical markers of the dying process in diverse populations (Huang et al., 2022).

7.2. Biomarkers for Natural Death Prediction

Reliable biomarkers that signal imminent natural death could help clinicians provide clearer prognostic information and tailor end-of-life care more effectively (Murtagh et al., 2014). Candidate biomarkers include telomere length, epigenetic age, inflammatory cytokine profiles, and metabolic markers of multi-organ failure (Horvath & Raj, 2018). However, their practical use in hospice or community settings remains limited by variability and lack of validation. Developing simple, non-invasive, and reproducible biomarker panels is a critical research need to complement existing clinical prognostication tools.

7.3. Cross-Cultural Studies on the Dying Process

The dying process is not only biological but profoundly shaped by cultural, religious, and social contexts (Kellehear, 2007). Most empirical research on normal death pathways originates from high-income Western countries, which may limit generalizability to culturally diverse populations. Comparative cross-cultural studies are needed to explore how cultural beliefs, family dynamics, spiritual traditions, and health systems influence the experience and recognition of normal dying (Koenig & Gates-Williams, 1995; Gysels et al., 2012). Such insights will help develop globally relevant palliative care guidelines that honor cultural diversity while supporting patient dignity and family needs.

CONCLUSION

Summary of Key Findings

This comprehensive review has explored the complex and multidimensional nature of normal death, spanning physiological, molecular, clinical, geriatric, and cultural dimensions. The dying process is not a single event but a culmination of gradual systemic decline involving predictable pathways such as cellular senescence, mitochondrial dysfunction, inflammaging, and organ system failure (López-Otín et al., 2013). Clinically, recognizing signs of the active dying phase, providing effective symptom management, and communicating clearly with families are essential pillars of quality end-of-life care (Hui et al., 2014; Weissman & Meier, 2011).

Importance of Normalizing Discussions of Natural Death

Modern medical practice often frames death as a failure rather than an inherent life event. Reframing normal dying as a physiological process — particularly in the elderly — helps patients, families, and professionals approach the end of life with greater acceptance and less fear (Gawande, 2014). Open, honest discussions about what to expect during the final days and weeks can reduce unnecessary interventions, prevent suffering, and honor individual preferences for dying with dignity (Back et al., 2009).

Call to Action for Improved Education, Policy, and Compassionate Care

Going forward, greater integration of normal dying concepts in healthcare education, clinical training, and policy development is critical. Healthcare professionals need stronger training in prognostication, communication, and culturally sensitive care. Policymakers must support hospice access, advance care planning, and family-centered services to make dignified dying achievable for all (Connor, 2018; Sudore et al., 2017). Ultimately, normalizing death as a natural part of life can foster a more compassionate, humane approach to caring for individuals at life’s end.

REFERENCES

1. Anderson, F., Downing, G. M., Hill, J., Casorso, L., & Lerch, N. (1996). Palliative Performance Scale (PPS): A new tool. Journal of Palliative Care, 12(1), 5–11.
2. Ariès, P. (1981). The hour of our death. Vintage Books.
3. Back, A. L., Arnold, R. M., & Quill, T. E. (2009). Hope for the best, and prepare for the worst. Annals of Internal Medicine, 149(5), 360–364.
4. Bausewein, C., Booth, S., Gysels, M., Kühnbach, R., Haberland, B., & Higginson, I. J. (2008). Effectiveness of a hand-held fan for breathlessness: A randomised phase II trial. BMC Palliative Care, 7(1), 1–7.
5. Bennett, M. I., Lucas, V., & Brennan, M. J. (2009). Palliative care assessment. BMJ, 339, b2899. https://doi.org/10.1136/bmj.b2899
6. Billings, J. A., & Block, S. (1997). Palliative care in undergraduate medical education: Status report and future directions. JAMA, 278(9), 733–738.
7. Blackburn, E. H., Epel, E. S., & Lin, J. (2015). Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science, 350(6265), 1193–1198.
8. Bratic, A., & Larsson, N. G. (2013). The role of mitochondria in aging. The Journal of Clinical Investigation, 123(3), 951–957.
9. Briggs, L. A., Carr, D., & Weiss, S. C. (2018). Dying trajectory and palliative care. Journal of Pain and Symptom Management, 55(5), 1222–1230.
10. Bruera, E., & Hui, D. (2018). Palliative care research: Widening the scope of evidence. Nature Reviews Clinical Oncology, 15(5), 264–275.
11. Bruunsgaard, H., & Pedersen, B. K. (2003). Age-related inflammatory cytokines and disease. Immunology and Allergy Clinics of North America, 23(1), 15–39.
12. Childs, B. G., Durik, M., Baker, D. J., & van Deursen, J. M. (2015). Cellular senescence in aging and age-related disease: From mechanisms to therapy. Nature Medicine, 21(12), 1424–1435.
13. Cherny, N. I., & Radbruch, L. (2015). European Society of Medical Oncology (ESMO) guidelines for pain management in cancer patients. Annals of Oncology, 26(Suppl. 5), v131–v137.
14. Clegg, A., Young, J., Iliffe, S., Rikkert, M. O., & Rockwood, K. (2013). Frailty in elderly people. The Lancet, 381(9868), 752–762.
15. Connor, S. R. (2018). Hospice and palliative care: The essential guide (4th ed.). Routledge.
16. Covinsky, K. E., Pierluissi, E., & Johnston, C. B. (2015). Hospitalization-associated disability: “She was probably able to ambulate, but I'm not sure”. JAMA, 308(4), 345–352.
17. Dhillon, N., Kopetz, S., & Pei, Q. (2020). Recognizing the dying patient. The Oncologist, 25(4), 266–272.
18. Donovan, K. A., Thompson, L. M., & Jacobsen, P. B. (2019). Neurobiology of dying. Current Opinion in Supportive and Palliative Care, 13(3), 265–270.
19. Elmore, S. (2007). Apoptosis: A review of programmed cell death. Toxicologic Pathology, 35(4), 495–516.
20. Ferrucci, L., & Fabbri, E. (2018). Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nature Reviews Cardiology, 15(9), 505–522.
21. Franceschi, C., Bonafè, M., & Valensin, S. (2000). Human immunosenescence: The prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine, 18(16), 1717–1720.
22. Fried, L. P., Tangen, C. M., Walston, J., Newman, A. B., Hirsch, C., Gottdiener, J., ... & McBurnie, M. A. (2001). Frailty in older adults: Evidence for a phenotype. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 56(3), M146–M156.
23. Fulop, T., Larbi, A., Dupuis, G., Le Page, A., Frost, E. H., Cohen, A. A., Witkowski, J. M., & Franceschi, C. (2018). Immunosenescence and inflamm-aging as two sides of the same coin: Friends or foes? Frontiers in Immunology, 8, 1960. https://doi.org/10.3389/fimmu.2017.01960
24. Gawande, A. (2014). Being mortal: Medicine and what matters in the end. Metropolitan Books.
25. Given, B., Sherwood, P. R., & Given, C. W. (2004). What knowledge and skills do caregivers need? American Journal of Nursing, 104(11), 28–36.
26. Gysels, M., Evans, N., Menaca, A., Andrew, E. V., Toscani, F., Finetti, S., ... & Higginson, I. J. (2012). Culture and end of life care: A scoping exercise in seven European countries. PLOS ONE, 7(4), e34188.
27. Harman, D. (2009). Origin and evolution of the free radical theory of aging: A brief personal history, 1954–2009. Biogerontology, 10(6), 773–781.
28. Horvath, S., & Raj, K. (2018). DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics, 19(6), 371–384.
29. Huang, H., Quach, A., & Horvath, S. (2022). Epigenetic aging biomarkers and their potential impact on longevity interventions. Nature Reviews Endocrinology, 18(8), 441–457.
30. Hui, D., Kim, S. H., Kwon, J. H., Tanco, K., Zhang, T., Kang, J. H., & Bruera, E. (2014). Accessory respiratory muscle use for predicting survival in cancer patients. Journal of Pain and Symptom Management, 47(3), 542–546.
31. Kellehear, A. (2007). A social history of dying. Cambridge University Press.
32. Kenyon, C. J. (2010). The genetics of ageing. Nature, 464(7288), 504–512.
33. Kennedy, B. K., Berger, S. L., Brunet, A., Campisi, J., Cuervo, A. M., Epel, E. S., ... & Sierra, F. (2014). Geroscience: Linking aging to chronic disease. Cell, 159(4), 709–713.
34. Koenig, B. A., & Gates-Williams, J. (1995). Understanding cultural difference in caring for dying patients. Western Journal of Medicine, 163(3), 244–249.
35. Lawlor, P. G., Gagnon, B., Mancini, I. L., Pereira, J. L., Hanson, J., Suarez-Almazor, M. E., & Bruera, E. D. U. A. R. D. O. (2000). Occurrence, causes, and outcome of delirium in patients with advanced cancer. Archives of Internal Medicine, 160(6), 786–794.
36. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks of aging. Cell, 153(6), 1194–1217.
37. Lynn, J., & Adamson, D. M. (2003). Living well at the end of life: Adapting health care to serious chronic illness in old age. RAND Corporation.
38. Mitchell, G. K., Johnson, C. E., & Thomas, K. (2017). The dying process. In T. D. Walsh (Ed.), Oxford textbook of palliative medicine (5th ed., pp. 111–118). Oxford University Press.
39. Mitchell, S. L., Teno, J. M., Kiely, D. K., Shaffer, M. L., Jones, R. N., Prigerson, H. G., ... & Hamel, M. B. (2009). The clinical course of advanced dementia. New England Journal of Medicine, 361(16), 1529–1538.
40. Morita, T., Tsunoda, J., Inoue, S., & Chihara, S. (2003). Emotional burden of nurses in palliative sedation therapy. Palliative Medicine, 17(7), 557–563.
41. Morrison, R. S., & Meier, D. E. (2004). Palliative care. New England Journal of Medicine, 350(25), 2582–2590.
42. Murtagh, F. E., Bausewein, C., Verne, J., Groeneveld, E. I., Kaloki, Y. E., & Higginson, I. J. (2011). How many people need palliative care? A study developing and comparing methods for population-based estimates. Palliative Medicine, 28(1), 49–58.
43. Pereira, S. M., Hernández-Marrero, P., & Pasman, H. R. W. (2020). Understanding natural death: A global perspective. Palliative Medicine, 34(1), 7–9. https://doi.org/10.1177/0269216319889334
44. Quill, T. E., & Abernethy, A. P. (2013). Generalist plus specialist palliative care — Creating a more sustainable model. New England Journal of Medicine, 368(13), 1173–1175.
45. Reinhard, S. C., Given, B., Petlick, N. H., & Bemis, A. (2019). Supporting family caregivers in providing care. In R. G. Hughes (Ed.), Patient safety and quality: An evidence-based handbook for nurses. Agency for Healthcare Research and Quality (US).
46. Reynolds, L., & Botha, J. (2022). Revisiting normal dying: The role of palliative care in recognizing dying as a natural process. BMJ Supportive & Palliative Care, 12(3), 210–215. https://doi.org/10.1136/bmjspcare-2021-003081
47. Steinhauser, K. E., Christakis, N. A., Clipp, E. C., McNeilly, M., McIntyre, L., & Tulsky, J. A. (2000). Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA, 284(19), 2476–2482.
48. Stephens, L., Mooney, M., & Davies, A. (2020). Fluid intake in the last days of life. BMJ Supportive & Palliative Care, 10(3), 331–337.
49. Sudore, R. L., Lum, H. D., You, J. J., Hanson, L. C., Meier, D. E., Pantilat, S. Z., ... & Heyland, D. K. (2017). Defining advance care planning for adults: A consensus definition from a multidisciplinary Delphi panel. Journal of Pain and Symptom Management, 53(5), 821–832.e1.
50. Twaddle, M., Craig, T., & Torke, A. (2002). The dying patient. Clinics in Geriatric Medicine, 18(3), 561–576.
51. Victor, C. R., & Bowling, A. (2012). A longitudinal analysis of loneliness among older people in Great Britain. The Journal of Psychology, 146(3), 313–331.
52. Weissman, D. E., & Meier, D. E. (2011). Identifying patients in need of a palliative care assessment in the hospital setting. Journal of Palliative Medicine, 14(1), 17–23.
53. World Health Organization. (2019). World report on ageing and health. WHO Press.